Stocks
Halozyme Therapeutics, Inc.HALO
NASDAQHealthcareBiotechnology$63.66+0.16%
Price as of · delayed, not real-time
Specializing in drug delivery technologies, this biopharma company develops enzyme-based platforms that enhance the efficacy of injectable therapeutics. Its ENHANZE technology is licensed to major pharmaceutical firms, creating a royalty-driven revenue model that attracts growth investors.
Market Cap: $7.5B52W Range: $47.50 – $82.22
Congressional Interest in Halozyme Therapeutics, Inc. (HALO)
4 members of Congress have disclosed 10 trades in Halozyme Therapeutics, Inc. (HALO), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 6 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
10
Unique Politicians
4
Buys
4
Sells
6
Who in Congress Is Trading HALO?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-09 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-03-24 | Gilbert Cisneros | sell | $1K – $15K |
| 2024-09-09 | Josh Gottheimer | sell | $1K – $15K |
| 2023-07-12 | Daniel Goldman | sell | $15K – $50K |
| 2022-12-06 | Josh Gottheimer | sell | $1K – $15K |
| 2022-08-05 | Josh Gottheimer | sell | $1K – $15K |
| 2021-08-20 | Josh Gottheimer | buy | $1K – $15K |
| 2020-10-22 | Gilbert Cisneros | buy | $1K – $15K |
| 2020-10-19 | Josh Gottheimer | buy | $1K – $15K |
| 2017-11-06 | Mark R Warner | sell | $500K – $1M |